Objective To establish a retinoblastoma model and provide an animal model for the new treatment of RB. Methods Forty CD1 postnatal day 1 mice were randomly divided into 4 groups ( A,B, C, D), 10 in each. We set the right eye of each mouse as experiment group and the left as control. Different density of RB-Y9 cells(A 2.0×107/ml,B 3.0×107/ml,C 3.5×107/ml,D 4.0×107/ml, 4 μl/one) were injected into the vitreous cavity of right eyes, and the left eyes were injected with the same volume of cell culture medium. We closely monitored the tumor growth after injection and found the most appropriate density of the cells for the model construction. We used HE staining to analyze the tumor formation and histology and convinced that the tumor was RB. Results After the cell injection, we found no tumor formation in control group and most mice in the experiment group had tumors. Different density of injeced cells resulted in different rates of survival and tumor formation: the rate of tumor formation in the above 4 groups were 20%,80%,100% and 100% and the survival rates were100%,80%,80% and 50%. We regarded the C group (the density of the cells was 3.5×107/ml) as the best model for the experiment. HE staining of the tumor tissues implied that the structure of right eyes were severely destroyed and the cells had different size and were irregularly shaped: some were circular, oval and others were polygonal or irregular. The tumor cells had less cytoplasm and bigger nuclei when compared with normal controls. Cells with more than 1-2 nuclei can be frequently observed. Conclusions By injecting RB-Y79 cells in the vitreous cavity of neonatal mice can successfully develop the RB mouse model.
Key words
CD1 postnatal day 1mice /
retinoblastoma /
transplanted tumor model
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Dimaras H, Kimani K, Dimba E A, et al. Retinoblastoma [J]. Lancet, 2012, 379(9844):1436-1446.
[2] Leal-Leal C, Flores-Rojo M, Medina-Sanson A, et al. A multicentre report from the Mexican Retinoblastoma Group[J]. Br J Ophthalmol, 2004, 88(8): 1074-1077.
[3] Broaddus E, Topham A, Singh A D. Incidence of retinoblastoma in the USA: 1975-2004[J]. Br J Ophthalmol, 2009, 93(1): 21-23.
[4] Shields C L, Shields J A. Diagnosis and management of retinoblastoma [J]. Cancer control, 2004,15(11):317-327.
[5] Rygaard J, Povsen C O. Heterotransplantation of a human malignant tumour to "nude" mice [J]. Acta Pathol Microbiol Scand,1969, 77(4): 758-760.
[6] Gallie B L, Albert D M, Wong J J, et al. Invest Ophthalmol [J]. Vis Sci, 1977, 16(3): 256-259.
[7] 易先金,倪 连, 王文吉,等. 人视网膜母细胞瘤裸小鼠移植瘤的建立及有关生物学特性的研究[J]. 中华眼科杂志, 1995, 31(2): 201-205.
[8] 孙 莹,吴 荒,张小猛, 等. 视网膜母细胞瘤Y79 细胞裸鼠玻璃体腔移植瘤模型的建立 [J]. 中国实验诊断学,2009, 13(10): 1363-1365.
[9] Chen D, Livne-bar I, Vanderluit J L, et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma [J]. Cancer cell, 2004,5(6): 539-551.
[10] MacPherson D, Sage J, Kim T, et al. Cell type-specific effects of Rb deletion in the murine retina [J]. Genes Dev, 2004,18(14): 1681-1694.
[11] Dyer M A, Bremner R. The search for the retinoblastoma cell of origin[J]. Nat Rev Cancer, 2005,5(2): 91-101.
[12] Zhang J, SchweersB, Dyer M A. The first knockout mouse model of retinoblastoma[J]. Cell Cycle, 2004,3(7): 952-959 .
[13] McFall R C, Sery T W, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma[J]. Cancer Res, 1977, 37(8): 1003-1010.
[14] Dyer M A, Rodriguez-Galindo C, Wilson M W. Use of preclinical models to improve treatment of retinoblastoma [J]. PLoS Med, 2005,2(10): e332.
PDF(3892 KB)
